TABLE 4.
Variable | Patients | HR (95% CI) | p-value |
Age per year | 453 | 1.03 (1.01–1.05) | 0.001 |
Female versus male | 453 | 1.04 (0.78–1.39) | 0.794 |
BMI per kg·m−2 | 355 | 0.98 (0.95–1.02) | 0.353 |
Ex/current smoker versus never-smoker | 438 | 1.17 (0.88–1.57) | 0.284 |
DLCO per % predicted | 367 | 0.96 (0.95–0.97) | <0.0001 |
FVC per % predicted | 407 | 0.98 (0.97–0.99) | <0.0001 |
GAP stage | 370 | 1.71 (1.24–2.36) | 0.0010 |
>6 months antifibrotic treatment | 453 | 0.67 (0.46–0.98) | 0.037 |
HR: hazard ratio; BMI: body mass index; DLCO: diffusing capacity of the lung for carbon monoxide; FVC: forced vital capacity. Bold indicates statistically significant p-values.